Vaccine Contract Manufacturing Market by Type, Function, Application

Description

List of Tables

[199 Pages Report] The Vaccine Contract Manufacturing Market size was estimated at USD 5.06 billion in 2023 and expected to reach USD 5.51 billion in 2024, at a CAGR 9.21% to reach USD 9.39 billion by 2030.

Vaccine contract manufacturing refers to outsourcing vaccine production processes to third-party organizations, known as contract manufacturing organizations (CMOs). These specialized companies possess the expertise, equipment, and facilities to produce vaccines at various stages, from initial development to full-scale production and packaging. Vaccine manufacturers partner with CMOs to expedite the development and manufacturing process, leverage specialized capabilities, manage costs, and ensure supply chain flexibility. The vaccine contract manufacturing market encompasses companies that provide a range of services on a contract basis for the pharmaceutical industry. This includes the production of vaccines at various stages, from early-stage development, such as preclinical trials, through to large-scale commercial production. It often involves upstream processes, such as antigen production, and downstream processes, including filling, finishing, and packaging. Vaccine contract manufacturers serve as critical partners for pharmaceutical firms, biotechnology companies, and research institutions that require additional capability or expertise in vaccine production. The vaccine contract manufacturing is growing due to increasing outbreaks of infectious diseases worldwide, growing governmental regulations and support for vaccine development, and rising vaccinations of newborns and children. However, the market faces certain challenges, such as the high cost associated with vaccines and the lack of proper storage infrastructure. On the other hand, technological advancements in mRNA vaccine technology and strategic partnerships and collaborations with governments and non-governmental organizations present potential opportunities for the vaccine contract manufacturing market.

KEY MARKET STATISTICS
Base Year [2023]	USD 5.06 billion
Estimated Year [2024]	USD 5.51 billion
Forecast Year [2030]	USD 9.39 billion
CAGR (%)	9.21%

Type: Growing adoption of attenuated vaccines to enhance immune systems

An attenuated vaccine uses a live version of the virus or bacteria that has been weakened, which cannot cause disease in people with healthy immune systems. This type of vaccine elicits a strong immune response and often requires fewer doses for long-term immunity. DNA vaccines employ a piece of genetic material from a pathogen to elicit an immune response. They direct the body's cells to produce an antigen that is native to the pathogen, prompting a specific immune response. DNA vaccines are still a relatively new technology and offer potential advantages in speed of development and stability, making them an interesting avenue for contract manufacturing. Inactivated vaccines contain viruses or bacteria that have been killed through physical or chemical processes. These vaccines do not pose a risk of causing the disease itself and are stable, making them suitable for a broad range of environments. Inactivated vaccines generally require adjuvants to enhance the immune response and may require multiple doses. Subunit vaccines include only the essential antigens of a virus or bacteria-rather than the whole pathogen. This approach minimizes the risk of side effects and is particularly useful when the pathogen cannot be cultivated in vitro or when the whole organism is unnecessary for immunization. Toxoid vaccines contain inactivated toxic compounds produced by bacteria that cause illness rather than the bacteria itself. These vaccines train the immune system to fight off the natural toxin, offering protection if the immunized individual ever encounters the actual pathogen. They are particularly useful for bacteria, such as Clostridium tetani, the cause of tetanus, where toxin production is the main cause of disease.

Function: Increasing usage of downstream processing formulations that involve the purification and formulation of the bioproducts

Downstream processing refers to the phase of vaccine manufacturing where the bulk product is refined and purified to meet regulatory standards and quality requirements. Key steps in downstream processing include the separation of cells and virus particles, removal of contaminants, and concentration and formulation of the vaccine. The need for downstream processing arises from the necessity to ensure that vaccines are safe, pure, and effective before they can be administered to the public. Upstream processing in vaccine manufacturing includes all steps necessary for the growth and initial harvest of the vaccine-producing biological system. This generally involves the culturing of cells or microorganisms that generate the vaccine antigen. The preference for cutting-edge upstream processing technologies stems from the fundamental need for consistent, scalable, and high-yield vaccine production.

Application: Rising potential of vaccine contract manufacturing for human use to protect populations against infectious diseases

The need for vaccine contract manufacturing in the human use segment is primarily driven by the global need to protect populations against infectious diseases. This segment encompasses the production of vaccines for a vast range of conditions, from annual influenza shots to immunizations against emerging public health threats, including COVID-19. Vaccine contract manufacturing for veterinary applications addresses the need for immunizations within animal populations, including both livestock and companion animals. The segment ensures the health of animals, which is crucial for food security and the prevention of zoonotic diseases that can transfer to humans.

Regional Insights

The Americas region, with countries such as the United States and Canada, is characterized by advanced healthcare systems and a high degree of health awareness among the population. The United States stands as a prominent country in vaccine research. It has a vibrant ecosystem for biotech patents, with the government, industry, and academia actively investing in new vaccine technologies. In South America, increasing investment in biotechnology, government incentives for pharmaceutical manufacturing, growing public health expenditure, and the presence of bio-manufacturing facilities support the adoption of vaccine contract manufacturing. Europe has a mature vaccine contract manufacturing industry, benefiting from high-quality manufacturing standards and a stringent regulatory landscape. European Union (EU) countries actively engage in research and innovation, with a strong network of biotech firms and research institutes. The Middle East, while historically reliant on imported vaccines, is gradually developing its vaccine manufacturing capabilities, with nations including the United Arab Emirates and Saudi Arabia investing in local production facilities. Africa's market is heavily influenced by global health initiatives and partnerships focused on providing access to vaccines for all economic backgrounds. Asia Pacific represents a dynamic and rapidly growing vaccine contract manufacturing market due to its large population base, increasing healthcare expenditures, and growing awareness of the need for immunizations. Nations such as India and China are at the forefront, with a substantial number of manufacturing facilities contributing to the global vaccine supply. China has made significant investments in biotech and vaccine innovation, emphasizing the importance of technological upgrades. Japanese companies are investing in next-generation vaccines, including mRNA and DNA-based vaccines, while the government supports research through initiatives.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Vaccine Contract Manufacturing Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Vaccine Contract Manufacturing Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Vaccine Contract Manufacturing Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc, Ajinomoto Bio-Pharma Services by Ajinomoto Co., Inc., Aton (Shanghai) Biotech Co., Ltd., Avid Bioservices, Inc., Catalent, Inc., Charles River Laboratories International, Inc., CSL Limited, Curia Global, Inc., Cytovance Biologics by Shenzhen Hepalink Pharmaceutical Group Co., Ltd., Emergent BioSolutions Inc., FUJIFILM Diosynth Biotechnologies U.S.A., Inc. by FUJIFILM Corporation, Gedeon Richter PLC, GlaxoSmithKline PLC, ICON PLC, IDT Biologika GmbH, KBI Biopharma, Inc. by JSR Corporation, Klocke Pharma-Service GmbH, Lonza Group Ltd., Merck KGaA, Moderna, Inc., Pfizer Inc., Pharmaceutical Product Development by Thermo Fisher Scientific Inc., Recipharm AB, Serum Institute of India, and Vetter Pharma-Fertigung GmbH & Co. KG.

Market Segmentation & Coverage

This research report categorizes the Vaccine Contract Manufacturing Market to forecast the revenues and analyze trends in each of the following sub-markets:

Type
- Attenuated Vaccine
- DNA Vaccines
- Inactivated Vaccine
- Subunit Vaccines
- Toxoid Vaccines

Function
- Downstream
  - Analytical & QC studies
  - Fill & Finish Operations
  - Packaging

Upstream
- Bacterial Expression Systems
- Baculovirus or Insect Expression Systems
- Mammalian Expression Systems
- Yeast Expression Systems

Application
- Human Use
- Veterinary

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam

Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Vaccine Contract Manufacturing Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Vaccine Contract Manufacturing Market?

3. What are the technology trends and regulatory frameworks in the Vaccine Contract Manufacturing Market?

4. What is the market share of the leading vendors in the Vaccine Contract Manufacturing Market?

5. Which modes and strategic moves are suitable for entering the Vaccine Contract Manufacturing Market?

Product Code: MRR-430D42AA0DC4

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Increasing demand for vaccines leading to capacity expansion by contract manufacturers
  - 5.1.1.2. Key advantages such as cost and time saving offered by contract services
  - 5.1.1.3. Vaccination coverage across the globe
- 5.1.2. Restraints
  - 5.1.2.1. Limited outsourcing by well-established vaccine manufacturers
- 5.1.3. Opportunities
  - 5.1.3.1. Rising global demand to cater to the growing population of varied age groups
  - 5.1.3.2. Innovation and robust vaccine pipeline
  - 5.1.3.3. Favorable government insights and guidelines to speed up the vaccine manufacturing
- 5.1.4. Challenges
  - 5.1.4.1. Pharma companies manufacturing operations in-house to gain strategic control
5.2. Market Segmentation Analysis
- 5.2.1. Type: Growing adoption of attenuated vaccines to enhance immune systems
- 5.2.2. Function: Increasing usage of downstream processing formulations that involve the purification and formulation of the bioproducts
- 5.2.3. Application: Rising potential of vaccine contract manufacturing for human use to protect populations against infectious diseases
5.3. Market Disruption Analysis
5.4. Porter's Five Forces Analysis
- 5.4.1. Threat of New Entrants
- 5.4.2. Threat of Substitutes
- 5.4.3. Bargaining Power of Customers
- 5.4.4. Bargaining Power of Suppliers
- 5.4.5. Industry Rivalry
5.5. Value Chain & Critical Path Analysis
5.6. Pricing Analysis
5.7. Technology Analysis
5.8. Patent Analysis
5.9. Trade Analysis
5.10. Regulatory Framework Analysis

6. Vaccine Contract Manufacturing Market, by Type

6.1. Introduction
6.2. Attenuated Vaccine
6.3. DNA Vaccines
6.4. Inactivated Vaccine
6.5. Subunit Vaccines
6.6. Toxoid Vaccines

7. Vaccine Contract Manufacturing Market, by Function

7.1. Introduction
7.2. Downstream
7.3. Upstream

8. Vaccine Contract Manufacturing Market, by Application

8.1. Introduction
8.2. Human Use
8.3. Veterinary

9. Americas Vaccine Contract Manufacturing Market

9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States

10. Asia-Pacific Vaccine Contract Manufacturing Market

10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam

11. Europe, Middle East & Africa Vaccine Contract Manufacturing Market

11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom

12. Competitive Landscape

12.1. Market Share Analysis, 2023
12.2. FPNV Positioning Matrix, 2023
12.3. Competitive Scenario Analysis
- 12.3.1. Vaxcyte and Lonza Expand Collaboration for Global Commercial Manufacturing of Broad-Spectrum Pneumococcal Conjugate Vaccines (PCVs)
- 12.3.2. Oxford Acquires ABL Europe From Institut Merieux For EUR 15 Mn
- 12.3.3. Pfizer Inks USD 183M Contract Manufacturing Deal With Samsung Biologics
12.4. Strategy Analysis & Recommendation

13. Competitive Portfolio

13.1. Key Company Profiles
13.2. Key Product Portfolio